These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 18665769)
1. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine. El Sahly HM; Keitel WA Expert Rev Vaccines; 2008 Aug; 7(6):713-9. PubMed ID: 18665769 [TBL] [Abstract][Full Text] [Related]
2. Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly. Curran MP; Leroux-Roels I Drugs; 2010 Aug; 70(12):1519-43. PubMed ID: 20687619 [TBL] [Abstract][Full Text] [Related]
3. Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity. Giezeman KM; Nauta J; de Bruijn IA; Palache AM Vaccine; 2009 Apr; 27(18):2414-7. PubMed ID: 19368782 [TBL] [Abstract][Full Text] [Related]
4. Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Sullivan SJ; Jacobson R; Poland GA Expert Rev Vaccines; 2010 Oct; 9(10):1127-33. PubMed ID: 20923264 [TBL] [Abstract][Full Text] [Related]
5. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly. Lina B; Fletcher MA; Valette M; Saliou P; Aymard M Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616 [TBL] [Abstract][Full Text] [Related]
7. The safety and immunogenicity of influenza vaccine in children with asthma in Mexico. Pedroza A; Huerta JG; Garcia Mde L; Rojas A; López-Martínez I; Penagos M; Franco-Paredes C; Deroche C; Mascareñas C Int J Infect Dis; 2009 Jul; 13(4):469-75. PubMed ID: 19084453 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of reactogenicity and immunogenicity of two influenza vaccines (vaxigrip and fluarix) in the season 1996-1997. Beran J; Prymula R; Chlíbek R; Rychlý R; Splino M; Douda P; Gál P Cent Eur J Public Health; 1998 Nov; 6(4):269-73. PubMed ID: 9919375 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years. Schmidt-Ott R; Schwarz T; Haase R; Sander H; Walther U; Fourneau M; Htun-Myint L; Sänger R; Schuster V Vaccine; 2007 Dec; 26(1):32-40. PubMed ID: 18022736 [TBL] [Abstract][Full Text] [Related]
16. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550 [TBL] [Abstract][Full Text] [Related]
17. A randomized, controlled trial in children to assess the immunogenicity and safety of a thimerosal-free trivalent seasonal influenza vaccine. Domachowske JB; Blatter M; Chandrasekaran V; Liu A; Jain VK; Fries L Pediatr Infect Dis J; 2012 Jun; 31(6):605-15. PubMed ID: 22333695 [TBL] [Abstract][Full Text] [Related]
18. Intanza(®): a new intradermal vaccine for seasonal influenza. Atmar RL; Patel SM; Keitel WA Expert Rev Vaccines; 2010 Dec; 9(12):1399-409. PubMed ID: 21105776 [TBL] [Abstract][Full Text] [Related]
19. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. Treanor JJ; Schiff GM; Couch RB; Cate TR; Brady RC; Hay CM; Wolff M; She D; Cox MM J Infect Dis; 2006 May; 193(9):1223-8. PubMed ID: 16586358 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of serological trials submitted for annual re-licensure of influenza vaccines to regulatory authorities between 1992 and 2002. Voordouw AC; Beyer WE; Smith DJ; Sturkenboom MC; Stricker BH Vaccine; 2009 Dec; 28(2):392-7. PubMed ID: 19878750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]